Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
What does it do?
Sanofi is a French pharmaceutical giant that makes medicines and vaccines used by millions of people every day. Their biggest product is Dupixent, an injection that treats eczema, asthma, and other conditions where the immune system goes haywire. They also make vaccines you may have had as a child, like ones protecting against polio and whooping cough. Think of them as one of the world's largest medicine factories, operating across dozens of countries.
Sanofi matters right now because Dupixent has become one of the fastest-growing drugs in the entire pharmaceutical industry, and investors are watching whether it can carry the whole company on its back. There is also a major strategic shift happening — Sanofi is spinning off its consumer health division (think over-the-counter products) to sharpen its focus on higher-margin prescription drugs and vaccines. That kind of focused bet on innovation is exactly what the market is paying attention to.
How does it make money?
Sanofi made $43.6 billion in revenue last year, up from $41.1 billion the year before, which is solid growth for a company this size. The biggest chunk comes from Dupixent, which alone generated over $13 billion in sales and is still growing fast. Vaccines are the second major pillar, with products sold to governments and health systems worldwide. The rest comes from specialty medicines treating rare diseases, cancer, and neurological conditions.
Why do investors care?
The core growth story is Dupixent — it is being tested for more and more conditions, meaning its addressable market (the number of patients who could use it) keeps expanding. If regulators approve it for new uses like chronic obstructive pulmonary disease (COPD), it could add billions more in annual sales. Investors also like that Sanofi is cutting costs and doubling down on its pipeline, meaning new drugs in development that could become future revenue drivers. What has to go right is that Dupixent avoids major safety surprises and new drugs in the pipeline actually reach patients.
Deep Dive
MemberA full investor briefing on Sanofi — history, leadership, risks, and outlook.